An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 305-314

  Zhong, Jixin ^a   Rao, Xiaoquan ^a   Rajagopalan, Sanjay ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; CD26; DPP4; Inflammation; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; LINAGLIPTIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ANTIINFLAMMATORY ACTIVITY; BIOCHEMISTRY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DENDRITIC CELL; DRUG TARGETING; ENZYME INACTIVATION; EXTRACELLULAR MATRIX; HEART PROTECTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; MOLECULAR INTERACTION; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INFLAMMATION; MICE;

EID: 84872424922     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.09.012     Document Type: Review

References (104)

1. Abbott C.A., Yu D.M., Woollatt E., Sutherland G.R., McCaughan G.W., Gorrell M.D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000, 267:6140-6150.
2. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol Sci 2009, 30:600-607.
3. McCaughan G.W., Wickson J.E., Creswick P.F., Gorrell M.D. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatology 1990, 11:534-544.
4. Iwaki-Egawa S., Watanabe Y., Kikuya Y., Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem 1998, 124:428-433.
5. Richard E., Arredondo-Vega F.X., Santisteban I., Kelly S.J., Patel D.D., Hershfield M.S. The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. J Exp Med 2000, 192:1223-1236.
6. Aertgeerts K., Ye S., Tennant M.G., et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004, 13:412-421.
7. Rasmussen H.B., Branner S., Wiberg F.C., Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003, 10:19-25.
8. Dong R.P., Tachibana K., Hegen M., et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997, 159:6070-6076.
9. Abbott C.A., McCaughan G.W., Levy M.T., Church W.B., Gorrell M.D. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem 1999, 266:798-810.
10. Gorrell M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005, 108:277-292.
11. Buhling F., Junker U., Reinhold D., Neubert K., Jager L., Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995, 45:47-51.
12. Buhling F., Kunz D., Reinhold D., et al. Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun 1994, 13:270-279.
13. Hegen M., Niedobitek G., Klein C.E., Stein H., Fleischer B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol 1990, 144:2908-2914.
14. Deacon C.F., Plamboeck A., Moller S., Holst J.J. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002, 282:E873-E879.
15. Rolin B., Deacon C.F., Carr R.D., Ahren B. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. Eur J Pharmacol 2004, 494:283-288.
16. Parker J.C., Lavery K.S., Irwin N., et al. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J Endocrinol 2006, 191:93-100.
17. Wakabayashi T., Kosaka J., Mochii M., et al. C38, equivalent to BM88, is developmentally expressed in maturing retinal neurons and enhances neuronal maturation. J Neurochem 2010, 112:1235-1248.
18. Deacon C.F., Plamboeck A., Rosenkilde M.M., de Heer J., Holst J.J. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metab 2006, 291:E468-E475.
19. Gault V.A., Parker J.C., Harriott P., Flatt P.R., O'Harte F.P. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 2002, 175:525-533.
20. Michel M.C., Beck-Sickinger A., Cox H., et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998, 50:143-150.
21. Haynes A.C., Arch J.R., Wilson S., McClue S., Buckingham R.E. Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor?. Regul Pept 1998, 75-76:355-361.
22. Naveilhan P., Hassani H., Canals J.M., et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 1999, 5:1188-1193.
23. Kos K., Baker A.R., Jernas M., et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 2009, 11:285-292.
24. Fadini G.P., Boscaro E., Albiero M., et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:1607-1609.
25. Morrison M.E., Vijayasaradhi S., Engelstein D., Albino A.P., Houghton A.N. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993, 177:1135-1143.
26. Ohnuma K., Yamochi T., Uchiyama M., et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci U S A 2004, 101:14186-14191.
27. Girardi A.C., Degray B.C., Nagy T., Biemesderfer D., Aronson P.S. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 2001, 276:46671-46677.
28. Weihofen W.A., Liu J., Reutter W., Saenger W., Fan H. Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26). J Biol Chem 2005, 280:14911-14917.
29. Cheng H.C., Abdel-Ghany M., Pauli B.U. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem 2003, 278:24600-24607.
30. Morimoto C., Torimoto Y., Levinson G., et al. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 1989, 143:3430-3439.
31. Martin M., Huguet J., Centelles J.J., Franco R. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J Immunol 1995, 155:4630-4643.
32. Tanaka T., Kameoka J., Yaron A., Schlossman S.F., Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci U S A 1993, 90:4586-4590.
33. Hegen M., Kameoka J., Dong R.P., Schlossman S.F., Morimoto C. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 1997, 90:257-264.
34. Torimoto Y., Dang N.H., Vivier E., Tanaka T., Schlossman S.F., Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991, 147:2514-2517.
35. Morimoto C., Schlossman S.F. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998, 161:55-70.
36. Yu D.M., Slaitini L., Gysbers V., et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol 2011, 73:102-111.
37. Ohnuma K., Munakata Y., Ishii T., et al. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol 2001, 167:6745-6755.
38. Ohnuma K., Inoue H., Uchiyama M., et al. T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol 2006, 16:3-13.
39. Mayo K.E., Miller L.J., Bataille D., et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003, 55:167-194.
40. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 1992, 89:8641-8645.
41. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
42. Portha B., Tourrel-Cuzin C., Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res 2011, 2011:376509.
43. Fleischer B., Sturm E., De Vries J.E., Spits H. Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol 1988, 141:1103-1107.
44. Mittrucker H.W., Steeg C., Malissen B., Fleischer B. The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. Eur J Immunol 1995, 25:295-297.
45. Tanaka T., Camerini D., Seed B., et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992, 149:481-486.
46. Kim S.J., Nian C., Doudet D.J., McIntosh C.H. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 2009, 58:641-651.
47. Kim S.J., Nian C., McIntosh C.H. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes 2010, 59:1739-1750.
48. Laudes M., Oberhauser F., Schulte D.M., et al. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. Exp Clin Endocrinol Diabetes 2010, 118:473-477.
49. Ohnuma K., Takahashi N., Yamochi T., Hosono O., Dang N.H., Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008, 13:2299-2310.
50. Ohnuma K., Yamochi T., Uchiyama M., et al. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol Cell Biol 2005, 25:7743-7757.
51. Ta N.N., Li Y., Schuyler C.A., Lopes-Virella M.F., Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010, 213:429-435.
52. Shah Z., Kampfrath T., Deiuliis J.A., et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124:2338-2349.
53. Hausenloy D.J., Yellon D.M. GLP-1 therapy: beyond glucose control. Circ Heart Fail 2008, 1:147-149.
54. Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010, 3:195-201.
55. Sauve M., Ban K., Momen M.A., et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59:1063-1073.
56. Zhang D., Huang W., Dai B., et al. Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am J Physiol Heart Circ Physiol 2010, 299:H1339-H1347.
57. Olinde K.D., O'Connell J.B. Inflammatory heart disease: pathogenesis, clinical manifestations, and treatment of myocarditis. Annu Rev Med 1994, 45:481-490.
58. Hansson G.K., Robertson A.K., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006, 1:297-329.
59. Savoia C., Schiffrin E.L. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006, 15:152-158.
60. Lahoute C., Herbin O., Mallat Z., Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 2011, 8:348-358.
61. Moubayed S.P., Heinonen T.M., Tardif J.C. Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 2007, 18:638-644.
62. Charo I.F., Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011, 10:365-376.
63. Reinhold D., Bank U., Buhling F., et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 1997, 91:354-360.
64. Schon E., Jahn S., Kiessig S.T., et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 1987, 17:1821-1826.
65. Reinhold D., Bank U., Buhling F., et al. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiology 1993, 188:403-414.
66. Reinhold D., Bank U., Buhling F., et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett 1997, 58:29-35.
67. Kahne T., Lendeckel U., Wrenger S., Neubert K., Ansorge S., Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 1999, 4:3-15.
68. Ludwig A., Schiemann F., Mentlein R., Lindner B., Brandt E. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol 2002, 72:183-191.
69. Shioda T., Kato H., Ohnishi Y., et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A 1998, 95:6331-6336.
70. 2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol 1998, 161:2672-2675.
71. Proost P., Struyf S., Schols D., et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999, 274:3988-3993.
72. Struyf S., Proost P., Schols D., et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999, 162:4903-4909.
73. Iwata S., Yamaguchi N., Munakata Y., et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999, 11:417-426.
74. Vittone F., Liberman A., Vasic D., et al. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 2012, 55:2267-2275.
75. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
76. Matheeussen V., Baerts L., De Meyer G., et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011, 392:189-198.
77. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011, 55:10-16.
78. Golpon H.A., Puechner A., Welte T., Wichert P.V., Feddersen C.O. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001, 102:81-86.
79. Basu A., Charkoudian N., Schrage W., Rizza R.A., Basu R., Joyner M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295.
80. Nystrom T., Gonon A.T., Sjoholm A., Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125:173-177.
81. Mason R.P., Jacob R.F., Kubant R., et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb 2011, 18:774-783.
82. Jackson E.K., Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 2008, 51:1637-1642.
83. Jackson E.K., Dubinion J.H., Mi Z. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 2008, 35:29-34.
84. Tanaka T., Nangaku M., Nishiyama A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr Opin Nephrol Hypertens 2011, 20:476-481.
85. Bergenstal R.M., Wysham C., Macconell L., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
86. Ogawa S., Ishiki M., Nako K., et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011, 223:133-135.
87. Mistry G.C., Maes A.L., Lasseter K.C., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008, 48:592-598.
88. Jadzinsky M., Pfutzner A., Paz-Pacheco E., Xu Z., Allen E., Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11:611-622.
89. Shirakawa J., Fujii H., Ohnuma K., et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011, 60:1246-1257.
90. Dobrian A.D., Ma Q., Lindsay J.W., et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 2011, 300:E410-E421.
91. Ta N.N., Schuyler C.A., Li Y., Lopes-Virella M.F., Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011, 58:157-166.
92. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
93. Kannel W.B., McGee D.L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59:8-13.
94. Pratley R.E., Kipnes M.S., Fleck P.R., Wilson C., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009, 11:167-176.
95. Pattzi H.M., Pitale S., Alpizar M., et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab 2010, 12:348-355.
96. Neumiller J.J., Setter S.M. Review of linagliptin for the treatment of type 2 diabetes mellitus. Clin Ther 2012, 34:993-1005.
97. Scheen A.J. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012, 38:89-101.
98. DeFronzo R.A., Burant C.F., Fleck P., Wilson C., Mekki Q., Pratley R.E. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:1615-1622.
99. Meneghini L.F., Orozco-Beltran D., Khunti K., et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011, 96:3337-3353.
100. Patil H.R., Al Badarin F.J., Shami H.A., et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012.
101. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
102. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf 2011, 6:304-309.
103. Lando H.M., Alattar M., Dua A.P. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012, 18(4):472-477.
104. Richard K.R., Shelburne J.S., Kirk J.K. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011, 33:1609-1629.